Status:
COMPLETED
A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery
Lead Sponsor:
Allergan
Conditions:
Bilateral LASIK Surgery
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
This study will compare the safety and efficacy of a new eye drop formulation with REFRESH PLUS® in participants following LASIK surgery.
Eligibility Criteria
Inclusion
- Patients scheduled for LASIK surgery in both eyes.
Exclusion
- Any systemic medication use within 3 months of screening (including over the counter, herbal, prescription, or nutritional supplement) which may affect dry eye or vision
- Use of topical eye medication other than prescribed for use in pre- or post-operative care
- Use of RESTASIS® or other topical ophthalmic cyclosporine product within 6 months prior to Screening
- Eye infection, inflammation, or allergy
- Soft contact lenses in the previous 7 days or rigid contact lenses in the previous 30 days prior to LASIK surgery.
Key Trial Info
Start Date :
August 20 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2014
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT01886690
Start Date
August 20 2013
End Date
August 18 2014
Last Update
April 16 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
New South Wales, Australia
2
Kelowna, British Columbia, Canada